ClinicalTrials.gg
RecruitingNCT04779008L-RIPC-CABGUpdated Sep 18, 2025

Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG

An interventional study of remote ischemic preconditioning (RIPC) in Coronary Disease, sponsored by Henan Institute of Cardiovascular Epidemiology. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Henan Institute of Cardiovascular Epidemiology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
73rd of 142
210 · median 220
Started
2021
with 19 others
No phase
87 of 224
27 open now
Primary completion
2025-12
later than 25 of 77 live
Registered
123rd of 224
by date
Lead sponsor
6 of 224
Henan Institute of Cardiovascular Epidemiology

Among the 224 studies in Coronary Disease with a site in China, this one is the 73rd largest by planned enrollment of the 142 interventional ones that give a count, is one of 20 that started in 2021, is one of 87 with no phase, reaches primary completion later than 25 of the 77 other live ones, and was the 123rd registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine,and Endothelin-1, and to observe MACCE event rates at 12 months.

Read the detailed description

A total of 210 patients were randomly divided into three groups according to the inclusion and exclusion criteria, with 70 patients in each group.

Experimental Group 1:

The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) 1 hours before surgery, then normal surgery, and RIPC was performed on the second day after surgery and every day after surgery, which lasted for 1 year.

Experiment Group 2:

Patients underwent once RIPC 1 hours before surgery, and then normal medical procedures were performed with no additional intervention.

Control group:

Patients did not receive any additional intervention. All patients were evaluated in three ways. First: 7days and 3 months after surgery , the quantitative examination of myocardial blood flow was conducted to observe the improvement of myocardial blood perfusion.

Second: The changes in the concentrations of vascular colorectal growth factor, Nitrc Oxide, adenosine, and endothelin-1.

Third, patients were evaluated for 6 months and 12months MACCE incidence (cardiovascular death, Nonfatal myocardial infarction, unplanned revascularization, and stroke).

03

Conditions studied

  • Coronary Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Three coronary artery lesions, CABG surgery was planned

Exclusion criteria

Exclusion Criteria:

  • The patients could not tolerate ripc;
  • peripheral vascular disease affecting upper limbs
  • Acute myocardial infarction complicated with cardiogenic shock,in recent 30 days,
  • Emergency cases
  • Severe structural heart disease and severe arrhythmia ;
  • The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;
  • Severe liver, renal and pulmonary disease
  • Mental disorder can't cooperate;
  • Inability to give ;
  • Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
  • pregnant;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Experimental Group 1

    Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.

    Other: remote ischemic preconditioning (RIPC)

  • Experimental
    Experimental Group 2

    Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.

    Other: remote ischemic preconditioning (RIPC)

  • No intervention
    Control group

    routine treatment, no RIPC

Interventions

  • Otherremote ischemic preconditioning (RIPC)

    Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.

06

What researchers measure

Primary outcomes

  1. Change of MBF by SPECT

    Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial blood flow(MBF)

    Time frame: 3 months

  2. Change of MPR by SPECT

    Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial perfusion reserve(MPR)

    Time frame: 3 months

  3. Change of MBF by CE

    Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial blood flow(MBF)

    Time frame: 3 months

  4. Change of MPR by CE

    Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial perfusion reserve(MPR)

    Time frame: 3 months

Secondary outcomes

  1. MBF by SPECT

    Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial blood flow(MBF)

    Time frame: 1 weeks

  2. MPR by SPECT

    Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial perfusion reserve(MPR)

    Time frame: 1 weeks

  3. MBF by CE

    Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial blood flow(MBF)

    Time frame: 1 weeks

  4. MPR by CE

    Myocardial perfusion was evaluated by contrast echocardiography(CE): and myocardial perfusion reserve(MPR)

    Time frame: 1 weeks

  5. Rate of major adverse cardiovascular and cerebrovascular events

    Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke

    Time frame: 12 months

  6. Rate of major adverse cardiovascular and cerebrovascular events

    Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke

    Time frame: 6 months

  7. Concentration of VEGF

    Blood vascular colorectal growth factor

    Time frame: -1days,1 weeks,3months post surgery

  8. Concentration of NO

    Blood Nitrc Oxide

    Time frame: -1days,1 weeks,3months post surgery

  9. Concentration of BK

    Blood bradykinin

    Time frame: -1days,1 weeks,3months post surgery

  10. Concentration of ET-1

    Blood endothelin-1

    Time frame: -1days,1 weeks,3months post surgery

  11. Concentration of adenosine

    Blood adenosine

    Time frame: -1days,1 weeks,3months post surgery

  12. Concentration of troponin

    Blood troponin

    Time frame: Before surgery and after surgery

  13. 6 minute Walk Test

    6 minute Walk Test

    Time frame: 1 weeks, 3/6/9 and 12 months post surgery

  14. Seattle angina questionnaire score

    Including the limited degree of physical activity, stable state of angina pectoris, angina attack frequency, treatment satisfaction, disease recognition and recognition of 5 dimensions.

    Time frame: 1 weeks, 3/6/9 and 12 months post surgery

  15. Change of LVEF by SPECT

    left ventricular ejection fraction was evaluated by Single Photon Emission Computed Tomography(SPECT):

    Time frame: 1 weeks, 3 months,6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008 Aug 1;79(3):377-86. doi: 10.1093/cvr/cvn114. Epub 2008 May 2. PubMed 18456674 ↗
  • Lau JK, Roy P, Javadzadegan A, Moshfegh A, Fearon WF, Ng M, Lowe H, Brieger D, Kritharides L, Yong AS. Remote Ischemic Preconditioning Acutely Improves Coronary Microcirculatory Function. J Am Heart Assoc. 2018 Oct 2;7(19):e009058. doi: 10.1161/JAHA.118.009058. PubMed 30371329 ↗
  • Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K; RIPHeart Study Collaborators. A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med. 2015 Oct 8;373(15):1397-407. doi: 10.1056/NEJMoa1413579. Epub 2015 Oct 5. PubMed 26436208 ↗
  • Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5. PubMed 26436207 ↗

Individual participant data

Plan to share: No — One year after the end of the trial, other outside investigators could access the original data on reasonable requests

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2025, 56 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 56 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Mar 3, 2021
StartActual
Mar 10, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2026
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04779008
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Mar 10, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 18, 2025

Study contacts

Quan Guo, MD
Contact
xinyiguoquan@163.com
+8615670510031
Muwei Li, Ph.D
principal investigator · Fuwai central China cardiovascular hospotial
Zhaoyun Cheng, Ph.D
principal investigator · Fuwai central China cardiovascular hospotial

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion